Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Finklea

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Advances in Nutrition (Bethesda, Md.)|February 15, 2012
Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studiesJames D Finklea, Ruth E Grossmann, Vin Tangpricha
Diagnostic Microbiology and Infectious Disease|June 10, 2018
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patientsJames D Finklea, Rita Hollaway, Karen Lowe, et al.
Diagnostic Microbiology and Infectious Disease|November 5, 2020
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosisPatrick J Nolan, Raksha Jain, Leah Cohen, et al.
Respiratory Medicine|April 6, 2010
Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasisJames D Finklea, Gul Khan, Sheree Thomas, et al.
Journal of Global Antimicrobial Resistance|December 22, 2021
Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adultsMarc D Esquivel, Marguerite L Monogue, Greg S Smith, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2023
Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftorAngela Wang, MinJae Lee, Ashley Keller, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 17, 2024
Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftorGregory A Ratti, Hannah Smith, Sasan Mirfakhraee, et al.
Journal of Palliative Medicine|May 9, 2020
End-of-Life Care in Cystic Fibrosis: Comparing Provider Practices Based on Lung Transplant CandidacyAllison V Lange, Ali Rueschhoff, Stephanie Terauchi, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 18, 2025
Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass indexAndrew Horvit, Katie Kaput, Amber Neece, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 18, 2026
Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosisAkruti Singh, Andrew Horvit, Jessica Abramowitz, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Advances in Nutrition (Bethesda, Md.)|February 15, 2012
Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studiesJames D Finklea, Ruth E Grossmann, Vin Tangpricha
Diagnostic Microbiology and Infectious Disease|June 10, 2018
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patientsJames D Finklea, Rita Hollaway, Karen Lowe, et al.
Diagnostic Microbiology and Infectious Disease|November 5, 2020
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosisPatrick J Nolan, Raksha Jain, Leah Cohen, et al.
Respiratory Medicine|April 6, 2010
Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasisJames D Finklea, Gul Khan, Sheree Thomas, et al.
Journal of Global Antimicrobial Resistance|December 22, 2021
Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adultsMarc D Esquivel, Marguerite L Monogue, Greg S Smith, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2023
Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftorAngela Wang, MinJae Lee, Ashley Keller, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 17, 2024
Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftorGregory A Ratti, Hannah Smith, Sasan Mirfakhraee, et al.
Journal of Palliative Medicine|May 9, 2020
End-of-Life Care in Cystic Fibrosis: Comparing Provider Practices Based on Lung Transplant CandidacyAllison V Lange, Ali Rueschhoff, Stephanie Terauchi, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 18, 2025
Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass indexAndrew Horvit, Katie Kaput, Amber Neece, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 18, 2026
Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosisAkruti Singh, Andrew Horvit, Jessica Abramowitz, et al.
Pageof 2